The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationHepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 1,970
Telaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Amorphous pharmaceutical solids: preparation, characterization and stabilization
Yu, L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00098-9 · Cited by 1,405
Epidemiology of hepatitis C virus infection
Alter, M. J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i17.2436 · Cited by 1,339
Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
(2009) · Handbook of Pharmaceutical Manufacturing Formulations · doi:10.3109/9781420081244-13 · Cited by 1,313
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Self-citationGhany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Self-citationAn NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Unravelling hepatitis C virus replication from genome to function
Lindenbach, B. D., & Rice, C. M. (2005) · Nature · doi:10.1038/nature04077 · Cited by 820
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
Self-citationSide effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1053/jhep.2002.36810 · Cited by 727
Kim, J. L., Morgenstern, K. A., Lin, C., Fox, T., Dwyer, M. D., Landro, J. A., Chambers, S. P., Markland, W., Lepre, C. A., O'Malley, E. T., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81351-3 · Cited by 727
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Self-citationVeldt, B. J., Heathcote, E. J., Wedemeyer, H., Reichen, J., Hofmann, W. P., Zeuzem, S., Manns, M. P., Hansen, B. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-10-200711200-00003 · Cited by 602
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
Bressanelli, S., Tomei, L., Roussel, A., Incitti, I., Vitale, R. L., Mathieu, M., De Francesco, R., & Rey, F. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13034 · Cited by 586
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1002/hep.1840360730 · Cited by 556
Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., & Hostomska, Z. (1996) · Cell · doi:10.1016/s0092-8674(00)81350-1 · Cited by 509
Structure of the hepatitis C virus RNA helicase domain
Yao, N., Hesson, T., Cable, M., Hong, Z., Kwong, A. D., Le, H. V., & Weber, P. C. (1997) · Nature Structural Biology · doi:10.1038/nsb0697-463 · Cited by 451
Self-citationReesink, H. W., Zeuzem, S., Weegink, C. J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.013 · Cited by 401
Self-citationBonkovsky, H. L., & Woolley, M. J. (1999) · Hepatology · doi:10.1002/hep.510290124 · Cited by 398
Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W., & Weber, P. C. (1999) · Structure · doi:10.1016/s0969-2126(00)80025-8 · Cited by 391
Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.899-909.2006 · Cited by 386
Self-citationNatural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients
Planas, R., Ballesté, B., Álvarez, M. A., Rivera, M., Montoliu, S., Galeras, J. A., Santos, J., Coll, S., Morillas, R. M., & Sola, R. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.01.005 · Cited by 359
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Self-citationHepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
(2010) · National Academies Press eBooks · doi:10.17226/12793 · Cited by 245
Lin, C., Kwong, A., & Perni, R. (2006) · Infectious Disorders - Drug Targets · doi:10.2174/187152606776056706 · Cited by 243
Self-citationPublic health impact of antiviral therapy for hepatitis C in the United States†
Volk, M. L., Tocco, R., Saini, S., & Lok, A. S. F. (2009) · Hepatology · doi:10.1002/hep.23220 · Cited by 224
Bartels, D. J., Zhou, Y., Zhang, E. Z., Marcial, M., Byrn, R. A., Pfeiffer, T., Tigges, A. M., Adiwijaya, B. S., Lin, C., Kwong, A. D., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/591141 · Cited by 211
Self-citationLin, K., Perni, R. B., Kwong, A. D., & Lin, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1813-1822.2006 · Cited by 200
Self-citationInstitute of Medicine Recommendations for the Prevention and Control of Hepatitis B and C
Mitchell, A. E., Colvin, H. M., & Beasley, P. R. (2010) · Hepatology · doi:10.1002/hep.23561 · Cited by 195
Bruno, S., Crosignani, A., Facciotto, C., Rossi, S., Roffi, L., Redaelli, A., de Franchis, R., Almasio, P. L., & Maisonneuve, P. (2010) · Hepatology · doi:10.1002/hep.23528 · Cited by 189
Jensen, D. M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandão-Mello, C. E., Reddy, K. R., Craxi, A., Martin, A. O., Teuber, G., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-8-200904210-00007 · Cited by 175
Peptide-based inhibitors of the hepatitis C virus serine protease
Llinàs-Brunet, M., Bailey, M., Fazal, G., Goulet, S., Halmos, T., Laplante, S., Maurice, R., Poirier, M., Poupart, M.-A., Thibeault, D., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00299-6 · Cited by 161
Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus
Morikawa, K., Lange, C. M., Gouttenoire, J., Meylan, E., Brass, V., Pénin, F., & Moradpour, D. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01451.x · Cited by 158
A long-term latent reservoir for HIV-1: discovery and clinical implications
Siliciano, J. D., & Siliciano, R. F. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh292 · Cited by 143
Hepatitis C virus NS3/4A protease
Kwong, A. D., Kim, J. L., Rao, G., Lipovšek, D., & Raybuck, S. A. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00043-6 · Cited by 126
Self-citationA new standard of care for the treatment of chronic HCV infection
Hofmann, W. P., & Zeuzem, S. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.49 · Cited by 124
Taremi, S. S., Beyer, B. M., Maher, M., Yao, N., Prosise, W. W., Weber, P. C., & Malcolm, B. A. (1998) · Protein Science · doi:10.1002/pro.5560071011 · Cited by 120
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Kieffer, T. L., Kwong, A. D., & Picchio, G. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp388 · Cited by 116
Self-citationSubstrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase
Bartenschlager, R. F. W., Ahlborn-Laake, L., Yasargil, K., Mous, J., & Jacobsen, H. (1995) · Journal of Virology · doi:10.1128/jvi.69.1.198-205.1995 · Cited by 115
Imperiale, T. F., Said, A. T., Cummings, O. W., & Born, L. J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02322.x · Cited by 111
New HCV therapies on the horizon
Vermehren, J., & Sarrazin, C. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03430.x · Cited by 110
Phenotypic Characterization of Resistant Val36Variants of Hepatitis C Virus NS3-4A Serine Protease
Zhou, Y., Bartels, D. J., Hanzelka, B. L., Müh, U., Wei, Y., Chu, H., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L. L., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00863-07 · Cited by 94
Self-citationLin, K. W., Kwong, A. D., & Lin, C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4784-4792.2004 · Cited by 79
Self-citationYip, Y. Y., Victor, F., Lamar, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.074 · Cited by 64
Vanwolleghem, T., Meuleman, P., Libbrecht, L. J., Roskams, T., Vos, R. D., & Leroux-Roels, G. G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.07.007 · Cited by 62
A review of HCV protease inhibitors.
Chen, K. X., & Njoroge, F. G. (2009) · PubMed · Cited by 56
Population-based hepatitis C surveillance and treatment in a national managed care organization.
Shatin, D., Schech, S. D., Patel, K., & McHutchison, J. G. (2004) · PubMed · Cited by 48
Telaprevir: A Promising Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Gentile, I., Viola, C., Borgia, F., Castaldo, G., & Borgia, G. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787581789 · Cited by 42
Mixing the right hepatitis C inhibitor cocktail
Gelman, M. A., & Glenn, J. S. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.005 · Cited by 39
Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials
Chary, A., & Holodniy, M. (2010) · Reviews on Recent Clinical Trials · doi:10.2174/157488710792007293 · Cited by 38
Treatment of Chronic Viral Hepatitis
Wright, M., Main, J., & Thomas, H. C. (2001) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020101200401 · Cited by 31
Treatment of Chronic Viral Hepatitis
Main, J., McCarron, B., & Thomas, H. C. (1998) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029800900601 · Cited by 31
Current Therapies for Chronic Hepatitis C
Ferguson, M. C. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.1.92 · Cited by 16
Pasquo, A., Nardi, M. C., Dimasi, N., Tomei, L., Steinkühler, C., Delmastro, P., Tramontano, A. L., & Francesco, R. D. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00060-1 · Cited by 14
Discovery and Development of Telaprevir
Grillot, A., Farmer, L. J., Rao, B. G., Taylor, W. P., Weisberg, I. S., Jacobson, I. M., Perni, R. B., & Kwong, A. D. (2011) · Wiley eBooks · doi:10.1002/9780470929353.ch15 · Cited by 11
Self-citation
Cited by
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Daina, A., & Zoete, V. (2016) · ChemMedChem · doi:10.1002/cmdc.201600182 · Cited by 2,549
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Unusual Amino Acids in Medicinal Chemistry
Blaskovich, M. A. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00319 · Cited by 635
Physical chemistry of supersaturated solutions and implications for oral absorption
Taylor, L. S., & Zhang, G. G. Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.006 · Cited by 392
Metadata
- Authors
- Kwong, A. D., Kauffman, R. S., Hurter, P., & Mueller, P.
- Venue
- Nature Biotechnology
- Published
- 2011-11
- Volume
- 29
- Issue
- 11
- Pages
- 993-1003
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2162287933
- Cited by
- 274
- References
- 69
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.